Current treatment protocols for CanL
| DRUGS | DOSE | MAIN SIDE EFFECTS |
| Meglumine antimoniate (a) | 100 mg/kg SC, SID or divided in two doses, for 4-6 weeks (initial reduced dosages for 2-3 days may be useful to detect any adverse events) (b) | Potential nephrotoxicity Pain and inflammation at injection site* |
| Miltefosine (a) | 2 mg/kg PO, once a day for 28 days | Disorexia Vomiting Diarrhea** |
| Allopurinol | 10 mg/kg PO, twice a day for at least 6-12 months (depending on the staging and the tolerance) | Xanthine urolithiasis Renal mineralization Nephrolithiasis*** |
| Domperidone (c) | 0,5 mg/kg PO, once a day for 1 month | Galactorrhea |
| Dietary nucleotides with AHCC (c) | Following manufacturer instructions PO, 6-12 months |
PO: per os; SC: subcutaneous
(a) Registered for veterinary use in most European countries; both therapies are recommended in combination with allopurinol.
(b) There is a limited number of studies on optimal treatment regimen.
Recommended dosages off-label but according to pharmacokinetic and clinical studies in dogs.
Treatment maybe extended by 2-3 weeks in patients stages II and III (without CKD) and with severe clinical picture or laboratory abnormalities.
(c) To be considered as monotherapy only for stage I.
* Injections should be administered in different skin sites.
** To reduce side effect administered always with food.
*** Monitoring side effects with urinalysis and abdominal ultrasound is recommended periodically.
Disclaimer: Information given here on drugs and dosages are based on a consensus of clinical and scientific experience by the LeishVet members. These recommendations have been published in scientific peer-reviewed scientific journals. Veterinary practitioners are requested to check with product leaflets and product registrations in their related country prior to any product selection and initiation of treatment.